Research
Hormonal
Insulin resistance (IR) and hyperinsulinemia are key etiological components of PCOS that drive excessive ovarian androgen production, leading to reproductive dysfunction, independent of but amplified by obesity.
Understanding that insulin resistance drives PCOS symptoms is crucial. Treating insulin resistance through diet and lifestyle can help reduce androgen levels and restore ovulation, even without significant weight loss.
GoodSupportsHIGH confidence
Even though several theories have been proposed to explain the pathogenic mechanism of PCOS, the role of insulin resistance (IR), independently of (but amplified by) obesity, is a key etiological component. IR is associated with consequent hyperinsulinemia, which activates excessive ovarian androgen production, leading to PCOS development.
Why this rating
Supported by multiple cited studies and consistent findings across the review.
Source
Polycystic Ovary Syndrome in Insulin-Resistant Adolescents with Obesity: The Role of Nutrition Therapy and Food Supplements as a Strategy to Protect Fertility
Valeria Calcaterra et al. · Nutrients · 2021
DOI 10.3390/nu13061848
narrative_reviewCited 171×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Medical nutrition therapy (MNT) and lifestyle interventions are the first-line treatment for adolescents with PCOS and obesity, aiming to restore ovulation and protect fertility by improving insulin resistance and metabolic function.Moderate
- Vigorous aerobic exercise (≥3 days/week, 30+ min, ≥60% VO2max) and combined resistance training improve insulin sensitivity and androgen levels in adolescents with PCOS.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →